This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In such scenarios, cardiologists’ primary form of treatment for children with coronary heart disease is a heartvalve implant. Unfortunately, the traditional pulmonaryvalves have a fixed diameter that can’t match the size of the child’s heart over time.
Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery. Raj Makkar, MD: Tricuspid regurgitation is a condition where the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium.
Background Percutaneous pulmonaryvalve implantation (PPVI) has emerged as a less invasive alternative for treating severe pulmonary regurgitation after tetralogy of Fallot (TOF) repair in patients with a native right ventricular outflow tract (RVOT).
Griepp , MD Professor in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai , was named as the new President of the HeartValve Society ( HVS ) at the 2024 HVS Annual Meeting on Wednesday, February 21, in Boston.
mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heartinnovation, addressing large unmet patient needs and supporting sustainable long-term growth.
In a remarkable leap forward for pediatric cardiac care, a groundbreaking partial heart transplant procedure has emerged as a beacon of hope for infants facing severe congenital heart conditions. This unique case presented an opportunity to utilize the heart after cardiac death through standard surgical techniques.
Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery. Raj Makkar, MD: Tricuspid regurgitation is a condition where the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content